Immunotherapy for prostate cancer

被引：13

作者：

Fong L. ^{[1
]}

Small E.J. ^{[1
]}

机构：

[1] University of California, San Francisco, San Francisco, CA 94143-0511

来源：

Current Oncology Reports | 2007年 / 9卷 / 3期

关键词：

Prostate Cancer; Advanced Prostate Cancer; Prostatic Acid Phosphatase; Prostate Stem Cell Antigen; Provenge;

D O I：

10.1007/s11912-007-0026-z

中图分类号：

学科分类号：

摘要：

Whereas androgen deprivation and chemotherapy have become the cornerstone of therapy for advanced prostate cancer, novel therapies are being developed that may expand upon currently available treatments. The identification of antigens expressed by prostate tissue and/or prostate cancer that are recognized by T cells or antibodies creates opportunities to develop novel immunotherapeutic approaches including tumor vaccines. Proteins expressed in prostate cancer - including prostate-specific antigen, prostatic acid phosphatase, and prostate membrane antigen - have been used as immunologic targets for immunotherapy. Moreover, innovations in cancer genomics and proteomics also will aid in the identification of immunologic targets. Emerging trials have demonstrated that immunotherapy may generate not only immune responses in patients but also clinical responses. Future studies will be directed at capitalizing on these findings. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：226 / 233

页数：7

共 62 条

[21]

Fong L., Benike C., Brockstedt D., Et al., Immunization with dendritic cells pulsed with xenogeneic prostatic acid phosphatase administered via different routes induces cellular immune responses in prostate cancer patients, Proc Amer Assoc Cancer Res, 40, (1999)

[22]

Small E.J., Fratesi P., Reese D.M., Et al., Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells, J Clin Oncol, 18, pp. 3894-3903, (2000)

[23]

Small E.J., Rini B., Higano C., Et al., A randomized, placebo-controlled phase iii trial of APC8015 (Provenge™) in patients with androgen-independent prostate cancer (AiPCa), Presented at the 39th Annual Meeting of the American Society of Clinical Oncology, (2003)

[24]

Small E.J., Schellhammer P.F., Higano C., Et al., Immunotherapy (APC8015) for androgen-independent prostate cancer (AIPC): Final survival data from a phase 3 randomized placebo-controlled trial, Paper presented at the 2005 Prostate Cancer Symposium, (2005)

[25]

Lu J., Celis E., Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen, Cancer Res, 62, pp. 5807-5812, (2002)

[26]

Murphy G., Tjoa B., Ragde H., Et al., Phase-I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen, Prostate, 29, pp. 371-380, (1996)

[27]

Murphy G.P., Tjoa B.A., Simmons S.J., Et al., Phase-II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment, Prostate, 39, pp. 54-59, (1999)

[28]

Tjoa B.A., Simmons S.J., Elgamal A., Et al., Follow-up evaluation of a phase-II prostate cancer vaccine trial, Prostate, 40, pp. 125-129, (1999)

[29]

Simons J.W., Mikhak B., Chang J.F., Et al., Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer, Cancer Res, 59, pp. 5160-5168, (1999)

[30]

Mincheff M., Tchakarov S., Zoubak S., Et al., Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: A phase I/II clinical trial, Eur Urol, 38, pp. 208-217, (2000)

← 1 2 3 4 5 6 7 →